Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
Hassan AwadaMina AbdelmalekTara CroninJeffrey BaronZakariya KashourFarhan AzadMuhammad Salman FaisalMark FaberMatthew GravinaPamela J SungSteven D GreenAmanda PrzespolewskiJames E ThompsonElizabeth A GriffithsEunice S WangPublished in: Blood cancer journal (2023)